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SUMMARY 
During the first wave of an influenza pandemic prior to the availability of an effective 
vaccine, healthcare workers (HCWs) may be at particular risk of infection with the 
novel influenza strain. We conducted a cross-sectional study of the prevalence of 
antibody to pandemic (H1N1) 2009 among HCWs in Hong Kong in February-March 
2010 following the first pandemic wave. Sera collected from HCWs were tested for 
antibody to H1N1 influenza virus by viral neutralization (VN). We assessed factors 
associated with higher antibody titers, and we compared antibody titers in HCWs with 
those in a separate community study. In total we enrolled 703 HCWs. Among 599 
HCWs who did not report receipt of pH1N1 vaccine, 12% had antibody titer ≥1:40 by 
VN. There were no significant differences in the age-specific proportions of 
unvaccinated HCWs with antibody titer ≥1:40 compared to the general community 
following the first wave of pH1N1. Under good adherence to infection control 
guidelines, potential occupational exposures in the hospital setting did not appear to 
be associated with any substantial excess risk of pH1N1 in HCWs. Most HCWs had 
low antibody titers following the first pandemic wave. 
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INTRODUCTION 
Prior to the availability of an effective vaccine, health care workers (HCWs) may 
have faced particular risk of pandemic (H1N1) 2009 infection. Infection of HCWs 
during a pandemic is of public health concern not only because of the impact of 
infection and illness on the HCWs themselves but also because HCWs have frequent 
contact with patients who could be predisposed to serious illness if infected with 
influenza, and substantial rates of absenteeism among HCWs could have adverse 
effects on the healthcare system.1 In 2009 the Institute of Medicine and the Centers 
for Disease Control and Prevention recommended that all healthcare workers who 
would have contact with suspected or confirmed pH1N1 patients should don N95 
respirators. Recommended practice in Hong Kong followed World Health 
Organization guidelines under which surgical masks should be routinely worn by all 
healthcare workers, standard droplet precautions should be implemented during 
contact with influenza patients, and greater precautions including face shields and 
N95 respirators used when performing aerosol-generating procedures.2   
 
The first imported pH1N1 case arrived in Hong Kong on April 30 and, after sporadic 
imported cases through May, local transmission was identified in mid-June3 The first 
wave peaked in September and had subsided by November.3, 4 pH1N1 was a 
notifiable condition throughout the first wave, and 36,000 laboratory-confirmed cases 
were notified including 1,400 HCWs, from a local population of 7 million including 
150,000 HCWs. The Hong Kong government provided pH1N1 vaccine (Sanofi 
Pasteur) for five target groups including HCWs starting December 21, 2009, and 
approximately 10% of local HCWs had received influenza vaccine by March 2010. 
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The infection attack rate among HCWs is likely to be greater than suggested by the 
notification rate (1400/150000=0.9%) because many symptomatic cases did not 
receive laboratory testing, while a fraction of pH1N1 infections are subclinical. Since 
few individuals below the age of 60 had detectable antibody to pH1N1 prior to the 
pandemic,4-6 serologic studies provide a straightforward way to infer infection attack 
rates.4, 5 We conducted a cross-sectional study of pH1N1 antibody among HCWs in 
Hong Kong following the first epidemic wave. 
 
METHODS 
Study design 
We recruited HCWs between February 11 and March 31, 2010 in 6 public hospitals 
comprising the Hong Kong West cluster of the local Hospital Authority, with a total 
workforce of around 7,000 HCWs in one acute care teaching hospital and five non-
acute hospitals. We established fixed study locations in each hospital, and participants 
were invited to attend our study site and participate in our study by open 
advertisement to all cluster employees. HCWs were eligible to participate if they were 
Hong Kong residents and had worked in the cluster for at least one month.  
 
We aimed to recruit at least 500 HCWs who had not received pH1N1 vaccine so that 
we could estimate the prevalence of antibody titer ≥1:40 to within ±3.5% overall and 
to within ±8% within 10-year age groups. The study protocol was approved by the 
Institutional Review Board of the University of Hong Kong/Hospital Authority Hong 
Kong West Cluster. 
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Laboratory methods 
Serum specimens collected from participants were kept in a refrigerated container at 
2-8ºC immediately after collection and delivered to the laboratory at the end of each 
working day for storage at -70ºC prior to testing. Sera were tested for antibody 
responses to A/California/04/2009 (H1N1) by a viral microneutralization (VN) assay 
using standard methods.4, 7 Because the VN assay was found to have greater 
sensitivity for pH1N1 infection than haemagglutination inhibition (HAI) in our 
previous study7 we used the VN assay as the primary serologic test in our study. We 
used a titer of 1:40 or greater as the threshold for seropositivity because in a previous 
study conducted in the same laboratory around 90% of patients with confirmed 
infection reached a titer of 1:40 or higher by VN at convalescence8 whereas few 
individuals had titer at or above 1:40 by VN before the first pandemic wave. A 
randomly selected subsets of specimens plus all specimens from participants who 
reported laboratory-confirmed pH1N1 infection were also tested by HAI using 
standard methods.7  
 
Statistical analysis 
We compared the differences in the proportion of HCWs with pH1N1 antibody titer 
≥1:40 between groups with chi-squared tests or Fisher’s exact test. We compared age-
specific proportions of HCWs with pH1N1 antibody titer ≥1:40 with antibody 
seroprevalence among blood donors determined from a separate community study 
also conducted after the first wave.4 We used logistic regression to explore factors 
associated with antibody titer ≥1:40. Factors that were statistically significant in 
univariable analyses were included in multivariable models. Multiple imputation was 
used to allow for a small amount of missing data on some characteristics.9  
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RESULTS 
A total of 703 HCWs were recruited; 104 HCWs who reported receipt of pH1N1 
vaccine were excluded from the following analyses. Among the 599 HCWs who 
reported that they had not received pH1N1 vaccine, 74 (12%) had pH1N1 antibody 
titer ≥1:40 by VN. In a random sample of 59/599 tested by HAI, 9 (15%) had 
antibody titer ≥1:40. There was a significant difference in the proportion of HCWs 
with antibody titer ≥1:40 by age, with greater proportion among younger HCWs, and 
by occupation, with greater proportion in doctors compared to nurses (Table I). In a 
multivariable analysis, age remained significantly associated with an antibody titer 
≥1:40 and HCWs working in the emergency room had a marginally significant higher 
probability of antibody titer ≥1:40 (p=0.06) (Table II).  
 
Among the 599 HCWs, 19 (3.2%) reported laboratory-confirmed pH1N1 infection 
during the first wave, and 58% (95% CI: 34%-80%) of those 19 had antibody titer 
≥1:40 by VN while 74% (95% CI: 49%-91%) had antibody titer≥1:40 by HAI. 
Among the 574 HCWs who did not report laboratory-confirmed pH1N1 infection, 
11% (95% CI: 8.5%-14%) had antibody titer ≥1:40 by VN. 338/599 (57%) HCWs 
reported experiencing a febrile influenza-like illness since July 2009 and 19% (95% 
CI: 15%-23%) of those HCWs had antibody titer ≥1:40 by VN versus 4.3% (95% CI: 
2.2%-7.6%) of the 255 HCWs who did not report influenza-like illness during the 
pandemic. 
 
Table III shows the comparison of pH1N1 antibody seroprevalence in HCWs versus 
blood donors at the Hong Kong Red Cross involved in a separate community study.4 
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There was no statistically significant difference in seroprevalence by age between 
HCWs and the community population in March 2010 apart from a marginally 
significant difference in HCWs aged 25-34y (p=0.09). In a multivariable logistic 
regression model for the HCW and community data combined (assuming none of the 
community blood donors were HCWs), the probability of antibody titer ≥1:40 varied 
significantly by age, but not by HCW status (OR=1.40, 95% CI: 0.94-2.08, p=0.09).  
 
DISCUSSION 
The first wave of 2009 pandemic H1N1 occurred between July and November 2009 
in Hong Kong.3, 4 The community infection attack rate in the first wave was estimated 
at around 11%, with much higher attack rates among children.4 In our study 19/599 
(3.2%) unvaccinated HCWs reported laboratory-confirmed pandemic H1N1 infection 
compared to an overall rate of 1% in HCWs in Hong Kong, while 12.4% of 
unvaccinated HCWs had antibody titre ≥1:40. Assuming the baseline seroprevalence 
in HCWs was similar to the community, the estimated infection attack rate in HCWs 
would have been around 4-15% in different age groups (Table III), suggesting that the 
majority of pH1N1 infections in HCWs were not laboratory-confirmed.  
 
Among unvaccined HCWs, 85% of HCWs who had pandemic influenza antibody titre 
≥1:40 reported febrile influenza-like illness during the pandemic. While some HCWs 
may have had antibody titer ≥1:40 prior to the pandemic, and others may have had a 
febrile illness not associated with influenza infection, these data are consistent with 
most pH1N1 infections being symptomatic. Therefore the World Health Organization 
recommendation that HCWs should withdraw from work while suffering acute 
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respiratory illness appears to be a very reasonable precaution to reduce the risk of 
nosocomial transmission. 
 
We did not identify statistically significant age-specific differences in seroprevalence 
in March 2010 between unvaccinated HCWs and blood donors from the general 
community (Table III), noting that vaccine coverage in the latter population was very 
low in March 2010 in Hong Kong. Thus our data are not consistent with an increased 
risk of pH1N1 infection in HCWs, which is in agreement with previous data 
indicating no excess risk of pandemic influenza in HCWs in Singapore10 or seasonal 
influenza infection in HCWs in Germany.11 We also found that there was no 
significant difference in seroprevalence between HCWs in an acute care hospital 
versus non-acute hospitals, between HCWs who did or did not have contact with 
suspected or confirmed pH1N1 patients, or by presence of school-age children at 
home (Table I). One study reported higher prevalence of pH1N1 antibody in HCWs 
in Taiwan compared to the general community, although age was strongly associated 
with seroprevalence, and age distributions differed between the HCW and community 
samples, possibly explaining the differences in seroprevalence.12 Infection control 
procedures in Hong Kong followed the World Health Organization guidelines. It is 
likely that the guidelines for the appropriate use of personal protective equipment 
were stringently adhered to following previous experiences with Severe Acute 
Respiratory Syndrome in 2003 as well as intensive control efforts from dedicated 
infection control teams.2Although we did not collect detailed data on adherence to 
infection control measures, another study reported that failure to adhere with standard 
precautions such as wearing a surgical mask during contact with suspected influenza 
patients was associated with an increased risk of pH1N1 infection.2 
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Factors associated with a higher risk of antibody titer ≥1:40 among unvaccined 
HCWs included younger age and working in the emergency room, whereas other 
factors such as occupation, number of occupational contact with influenza patients, 
and seasonal influenza vaccination history were not significantly associated with risk 
of antibody titer ≥1:40 (Tables I and II). Younger HCWs were more likely to have 
antibody titer ≥1:40, consistent with higher population attack rates in younger age 
groups,4 although potentially confounded by differences in age-specific ability to 
mount antibody response to infection. As the first point of contact with most influenza 
patients in a hospital setting is the emergency room, while many patients with 
influenza-like illness are not admitted, it is plausible that HCWs in the emergency 
room could face the highest and most frequent risk of infection. In addition, HCWs in 
the emergency room would tend to see patients earliest in their course of disease, 
when they might be most infectious.13  
 
Influenza vaccination is the best primary prevention measure against infection, and 
HCWs are often one of the target groups to receive vaccine not only for their direct 
protection both in the healthcare setting as well as in the community, but also to 
indirectly protect patients against nosocomial transmission.1, 11 In Hong Kong, HCWs 
were one of the target groups for pH1N1 vaccine, but coverage was low following 
intense media coverage of a series of adverse events potentially associated with 
pH1N1 vaccine. Around 15% of HCWs in our study reported receipt of one dose of 
pH1N1 vaccine, compared to overall vaccine coverage of around 10% of HCWs in 
Hong Kong. While our results suggest that following World Health Organization 
guidelines for infection control were sufficient to prevent substantial excess risk of 
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pH1N1 associated with occupational exposures in a hospital setting, vaccination is 
still important for protection of HCWs against infection in other settings. 
 
It is important to note several limitations of our study. Firstly, we conducted a cross-
sectional seroprevalence study following the first pH1N1 wave, and we did not have 
baseline (pre-pandemic) data to enable us to infer accurately attack rates among 
HCWs. Analysis of serological data may misclassify the infection status of some 
individuals. However, few adults in Hong Kong had antibody to pH1N1 at titer of 
1:40 or greater prior to the first wave (Table III),4 while most individuals infected 
with pH1N1 did go on to develop antibody titers ≥1:40.5 Secondly, while we did not 
observe any substantial excess risk of pH1N1 infection in HCWs compared to the 
general community, it is possible that a smaller excess risk could exist but have been 
masked by community exposures in our study. Larger and more detailed studies of 
HCWs are certainly warranted to help understand the risk of nosocomial infection and 
the effectiveness of preventive measures. Thirdly, participants in our study were a 
convenience sample covering HCWs in both acute and non-acute hospitals, while a 
random sample would have been ideal albeit more difficult to implement with a high 
response rate. Finally, we recruited HCWs who were working in 6 public hospitals on 
Hong Kong island and our results may not generalize to HCWs working in other 
regions of Hong Kong or local private hospitals and outpatient clinics.  
 
Our data suggest that in general HCWs in hospitals in Hong Kong, operating under 
the WHO infection control guidelines, did not have a higher risk of infection 
associated with their occupation compared to the general community. Furthermore, 
following the first pandemic wave, most HCWs did not have antibody titers at levels 
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that would typically be considered protective against infection, since vaccine uptake 
was very low.  
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Table I. Characteristics of 599 healthcare workers who had not received pandemic 
(H1N1) 2009 vaccine. 
Characteristic No. Proportion with antibody 
titer ≥1:40 by VN (95% CI)a 
p-valueb 
Age     
   19-24 years 49 16% (7.3%-30%)  
   25-34 years 125 20% (13%- 28%)  
   35-44 years 162 13% (8.2%-19%)  
   45-54 years 190 7.4% (4.1%-12%)  
   55-64 years 72 8.3% (3.1%-17%) 0.01 
   Unknown 1    
     
   Male 106 15% (8.9%-23%)  
   Female 493 12% (9.1%-15%) 0.43 
     
Occupation     
   Doctor 30 20% (7.7%-39%)  
   Nurse 146 8.2% (4.3%-14%)  
   Clinical supporting    235 9.4% (6.0%-14%)  
   Non-clinical supporting 144 17% (12%-25%)  
   Other 44 21% (9.8%-35%) 0.02 
     
Department     
   Medicine 83 9.6% (4.3%-18%)  
   Surgery 54 14.8% (6.6%-27%)  
 16 
   Emergency room 9 33.3% (7.5%-70%)  
   Pediatrics 38 10.5% (2.9%-25%)  
   Other clinical departments 255 11.8% (8.1%-16%)  
   Non-clinical 147 13.6% (8.5%-20%) 0.44 
   Unknown 13    
     
Contact with influenza 
patients Aug-Oct 2009 
    
   0 per day 171 13% (8.2%-19%)  
   1-5 per day 230 11% (7.5%-16%)  
    ≥ 6 per day 75 12% (5.6%-22%) 0.89 
   Unknown 123    
     
Acute care hospital 458 13% (10%-16%)  
Non-acute care hospital 141 11% (6.1%-17%) 0.57 
     
Number of school-age 
children at home 
    
   0 381 12% (9.2%-16%)  
   1 116 10% (5.5%-17%)  
   ≥2 94 14% (7.6%-23%) 0.74 
  Unknown 8    
     
Received 2009-10 seasonal 
influenza vaccine 
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   No 402 13% (9.6%-16%)  
   Yes 196 12% (7.6%-17%) 0.84 
   Unknown 1    
     
Received 2008-09 seasonal 
influenza vaccine 
    
   No 368 13% (9.3%-16%)  
   Yes 227 12% (8.4%-17%) 0.95 
   Unknown 4    
     
Received 2007-08 seasonal 
influenza vaccine 
    
   No 357 12% (9.1%-16%)  
   Yes 236 12% (8.4%-17%) 0.91 
  Unknown 6    
a Proportion of individuals with antibody titer ≥1:40 to A/CA/04/2009 by viral 
neutralization. 
b p-values for association calculated by chi-squared tests or fisher’s exact tests. 
CI: confidence interval; VN: viral neutralization 
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Table II. Univariable and multivariable analysis of factors associated with antibody 
titer ≥1:40 to pandemic (H1N1) 2009 among 599 healthcare workers who had not 
received pandemic (H1N1) 2009 vaccine. 
Characteristica Crude odds ratio of titer 
≥1:40 (95% CI) 
 Adjusted odds ratiob of 
titer ≥1:40 (95% CI) 
Age, years      
   19-24 0.78 (0.32-1.87)  0.74 (0.31-1.80) 
   25-34 1.00   1.00  
   35-44 0.59 (0.32-1.12)  0.55 (0.29-1.06) 
   45-54 0.32 (0.16-0.64)  0.28 (0.13-0.57) 
   55-64 0.36 (0.14-0.93)  0.32 (0.12-0.85) 
      
Department      
   Medicine 1.00   1.00  
   Surgery 1.58 (0.56-4.52)  1.57 (0.54-4.57) 
   Emergency room  4.53 (0.94-21.89)  4.56 (0.91-22.87) 
   Pediatrics 1.06 (0.30-3.75)  1.07 (0.30-3.87) 
   Other clinical dept 1.24 (0.54-2.84)  1.33 (0.57-3.09) 
   Non-clinical 1.46 (0.61-3.49)  2.07 (0.84-5.12) 
a Multiple imputation was used to adjust for a small amount of missing data on some 
characteristics. 
b Adjusted for the variables that were significant in univariable analyses i.e. age and 
department. 
c Contact with patients with suspected or confirmed pH1N1 between August and 
October 2009. 
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Table III. Comparison in prevalence of antibody titer ≥1:40 to pandemic (H1N1) 2009 in health care workers versus blood donors. 
Age  General community (blood donors) Healthcare workers p-valueb 
 June 2009 November-December 2009 March 2010 February-March 2010  
 n/Na % (95% CI) n/Na % (95% CI) n/Na % (95% CI) n/Na % (95% CI)  
18-24y 8/287 2.8% 
(1.2%-5.4%) 
96/548 18%       
(14%-21%) 
20/114 18%      
(11%-26%) 
8/49 16%       
(7.3%-30%) 
0.97 
25-34y 14/292 4.8% 
(2.6%-7.9%) 
94/763 12%       
(10%-15%) 
15/130 12%        
(6.6%-18%) 
25/125 20%       
(13%-28%) 
0.09 
35-44y 13/286 4.5% 
(2.4%-7.6%) 
54/604 8.9%        
(6.8%-12%) 
13/122 11%        
(5.8%-18%) 
21/162 13%       
(8.2%-19%) 
0.68 
45-54y 11/332 3.3% 
(1.7%-5.9%) 
26/367 7.1%        
(4.7%-10%) 
4/81 4.9%        
(1.4%-12%) 
14/190 7.4%        
(4.1%-12%) 
0.60 
55-64y 2/163 1.2% 
(0.1%-4.4%) 
6/131 4.6%        
(1.7%-10%) 
1/19 5.3%        
(0.1%-26%) 
6/72 8.3%        
(3.1%-17%) 
1.00 
a Number with antibody titer ≥1:40 to pandemic (H1N1) 2009 by viral neutralization / total number of subjects. 
b p-value comparing healthcare workers in March 2010 with the community sample in March 2010 by chi-squared test. 
